All
Venclexta Plus Mavenclad Boosts Response Rates in AML, MDS
The Venclexta-based regimen improved complete response rates in patients with acute myeloid leukemia and myelodysplastic syndromes.
Heart Risk May Occur Less With Some BTK Inhibitors in B-Cell Blood Cancers
In patients with certain B-cell blood cancers, heart-related side effects may occur less after receiving second-generation BTK inhibitors.
Brukinsa Supported as First-Line Treatment for Patients With CLL/SLL
Patients with treatment-naive CLL/SLL experienced long-term improved efficacy when treated with Brukinsa compared with bendamustine plus Rituxan.
Pelabresib Plus Jakafi Maintains Efficacy in JAK-Naive Myelofibrosis
Adding pelabresib to a JAK inhibitor may improve multiple aspects of myelofibrosis, including spleen size, symptoms and bone marrow fibrosis.
The Cancer Christmas Photo
One year, after breast cancer treatment, I decided to have a Christmas photoshoot with my family, which turned out to be a good laugh in the end.
Tecvayli Effective Maintenance Therapy in Newly Diagnosed Multiple Myeloma
Tecvayli alone or plus Revlimid has been found to be safe and may result in high MRD-negativity rates.
Darzalex Faspro May Improve Progression, Survival in Smoldering Multiple Myeloma
The risk for disease progression or death was reduced by 51% with subcutaneous Darzalex Faspro in certain patients with smoldering multiple myeloma.
Brain Cancer Survivor Reflects on Memoir and Her Journey
Maggie Bushway reflected on her memoir “Pearls: A Memoir on Childhood Cancer and Hope,” and her journey of healing and resilience after brain cancer.
Calquence Plus Venclexta Combo May Improve Survival in Frontline CLL
Calquence plus Venclexta, with or without Gazyva, improved progression-free survival over the standard-of-care chemoimmunotherapy in patients with untreated chronic lymphocytic leukemia.
Scemblix May Outperform Standard Treatments for Chronic Myeloid Leukemia
Scemblix resulted in better outcomes and fewer side effects compared to standard tyrosine kinase inhibitor therapies in patients with chronic myeloid leukemia.
Navtemadlin Shows Biomarker Response in Patients with R/R Myelofibrosis
Patients with relapsed or refractory (R/R) myelofibrosis experienced reduced biomarkers of disease severity following treatment with navtemadlin.
Tecartus Shows Similar Efficacy Across Age Groups in Leukemia
Tecartus demonstrated similar effectiveness across age groups of patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Revuforj Continues to Elicit Meaningful Responses in Some With Acute Leukemia
Long-term follow-data shows Revuforj to be effective in the treatment patients with R/R KMT2Ar acute leukemias.
D-VRd May Improve Minimal Residual Disease Responses in Multiple Myeloma
For patients with transplant-ineligible or -deferred newly diagnosed multiple myeloma, the addition of Darzalex to VRd improved MRD responses as well as progression-free survival.
Smoking May Be Linked With Genetic Mutations, Progression Risk in MDS
Results from the study also showed the potential association between smoking, disease progression and survival in patients with myelodysplastic syndromes.
CAR-T Cell Therapy Shows EFS Benefit in Pediatric Leukemia Subset
Treatment with bicistronic CD19/CD22 CAR-T cell therapy has shown event-free survival improvements in children with relapsed or refractory B-ALL.
Blincyto With Chemo May Improve Disease-Free Survival in Pediatric B-ALL
Pediatric patients with standard-risk B-ALL demonstrated significantly improved disease-free survival with Blincyto plus chemotherapy versus chemotherapy alone.
CURE Honors Seven Honorees at MPN Heroes Event
CURE celebrated seven MPN Heroes, who ranged from patients to medical professionals, on the contributions they made in the community.
SBRT May Be Effective in Managing Intermediate-Risk Prostate Cancer
Treatment with five-fraction SBRT could be effective versus traditional radiation in certain patients with low- or intermediate-risk prostate cancer.
The ABCs of ADCs in Breast Cancer
Since 2000, antibody-drug conjugates have been approved by the Food and Drug Administration for various cancer types, such as breast cancer.
After Cancer, My Doctors Assume Everything I Have Is Cancer
When you’ve had cancer do doctors assume every ailment is cancer for you?
‘Rocky’ Series Star Dolph Lundgren is Cancer-Free, Boxer Israel Vazquez Died of Cancer and More
From a Hollywood star sharing an uplifting update to the death of a three-time boxing champion, here’s what’s happening in the cancer space this week.
MRIs May Predict Organ Preservation, Survival in Rectal Cancer
MRIs were able to predict organ preservation and survival with the “watch-and-wait” approach in patients with rectal cancer.
Lenvima Combo Misses End Goal in Children with Osteosarcoma
Combination therapy of Lenvima with Ipex and Vepesid misses end goal in children with osteosarcoma, but further research is needed.
Finding Hope With Antibody-Drug Conjugates in Managing Breast Cancer
With more than 150 treatments being studied in clinical trials, what is on the horizon for antibody-drug conjugates in breast cancer?
My Expectations of Follicular Lymphoma Treatment
When I started receiving treatment for follicular lymphoma, I wasn’t sure what to expect regarding treatment — and a lot of things were unexpected.
‘Too Young For Cancer’ Author on the Importance of Advocating for Yourself
Author and kidney cancer survivor Katie Coleman explains why patients with cancer need to advocate for themselves when navigating the medical system.
FDA Grants Fast Track Designation to R289 in Lower-Risk MDS
The novel treatment is being evaluated for patients with previously treated transfusion-dependent lower-risk myelodysplastic syndrome.
FDA OKs Imfinzi for Limited-Stage Small Cell Lung Cancer
Imfinzi was approved by the FDA for the treatment of adults with limited-stage small cell lung cancer without disease progression after chemotherapy and radiation.
FDA Approves Bizengri for Some with NSCLC, Pancreatic Adenocarcinoma
The FDA has approved the first systemic therapy for patients with NSCLC or pancreatic adenocarcinoma with an NRG1 gene fusion.
